Rarely has shaving & raising $ for #prostateCancer and #GUcancers been such silly fun. Thanks to local #firstResponders & #MorrisvilleFiremen who showed up to support @DukeGUcancer at our Beers and Beards for Bros shave off @https://duke.is/bros

Celebrating Movember USA with our DCI Center for Prostate & Urologic Cancers amazing team at our annual retreat! Dan George. Join us Friday 12/1 at Fullsteam Brewery to support our hairy faces and a great cause! Duke Cancer

WATCH: Dan George of Duke Cancer discusses managing adverse events associated with PARP inhibitor therapy in patients with prostate cancer. #pcsm | Duke Health

ow.ly/gVTE50PqbLo

82K Challenge: swim 8,200 meters each week; raise $8,200.
Week 1: 8,200 meters
Week 2: 8,975 meters
Week 3: 2,750 meters (so far).
I am doing the swimming part of the 82k challenge, but I need $6200 more on the fundraising side. Please help if you can.

Check out KillCorporateAmerica blog series @ when/why someone w #kidneycancer benefits from #CytoreductiveNephrectomy . Patient-friendly language as always from KCA blogger & my wife D'Ann George. Thanks @JoseKaram@EricJonasch 4 interviews. #PaulLaudadio for pic of his family
Duke Cancer

Building team to swim 82k laps 4 Kidney Cancer. BTW 'I don't swim' is no excuse. Pat invented 'swim running' and wife Judy uses a snorkel. They blow each other kisses between laps! QR code donates $ to Kidney Cancer Association. DM me your # of laps Duke Health DCI Center for Prostate & Urologic Cancers

Christopher Wallis (he/him/his) met with Andrew Armstrong while at #ASCO23 to discuss how an #AI -derived digital pathology-based biomarker might predict potential benefits of long-term ADT with radiotherapy in #prostatecancer . Watch now: buff.ly/3MWMESC

Meta-analysis reveals on treatment PSA≤0.1 and PSA≤0.2 prognostic for OS in pts with mHSPC. Timing and extent of metastasis also prognostic, identifying subgroups for consolidative XRT. #ASCO23 #SusanHalabi DCI Center for Prostate & Urologic Cancers w Christopher Sweeney, MBBS

A key take a way message from #ASCO23 : ARTIFICIAL INTELLIGENCE is just around the corner to be used in daily practice to choose pts treatmt in #ProstateCancer Amazing presentation & work from Andrew Armstrong & cols. Dipcan OncoAlert UroToday.com MD Anderson Madrid Genomcore

Microbiome metabolites associated with worse outcomes on immunotherapy in RCC pts. Thrilled to welcome Shahla Bari to DCI Center for Prostate & Urologic Cancers. Thanks Prostate Cancer Foundation
for her #YoungInvestigatorAward

Meta-analysis reveals on treatment PSA≤0.1 and PSA≤0.2 prognostic for OS in pts with mHSPC. Timing and extent of metastasis also prognostic, identifying subgroups for consolidative XRT. #ASCO23 #SusanHalabi DCI Center for Prostate & Urologic Cancers w Christopher Sweeney, MBBS

#PANTHER results: median rPFS was 2x as long for Black men as whites & blacks had 2 x rate of complete PSA response, 49% and 28%, respectively. Compared to Abi Race, Black men had double PFS and half death rate at 2 years. Duke Cancer #PaulLeger #ASCO23 MedStar Georgetown

Andrew Armstrong leveraging #AI to predict patients who would benefit from long-term #ADT in locally advanced #prostate cancer
#ASCO23 OncoAlert

Microbiome metabolites associated with worse outcomes on immunotherapy in RCC pts. Thrilled to welcome Shahla Bari to DCI Center for Prostate & Urologic Cancers. Thanks Prostate Cancer Foundation
for her #YoungInvestigatorAward

Great presentation by Andrew Armstrong and NRG validating a predictive AI path biomarker in men with prostate cancer undergoing ADT + RT. Some high risk men may be able to avoid long term ADT! Dan George NRG @

AI predicts for who needs 2 yrs of ADT with RT and who can be treated with 4-6 months. Both prognostic and predictive. Trained &validated with OS prediction. ⁦Andrew Armstrong⁩ ⁦@paulnguyen2233⁩ ⁦⁦Daniel E Spratt⁩

#PANTHER results: median rPFS was 2x as long for Black men as whites & blacks had 2 x rate of complete PSA response, 49% and 28%, respectively. Compared to Abi Race, Black men had double PFS and half death rate at 2 years. Duke Cancer #PaulLeger #ASCO23 MedStar Georgetown

Docetaxel plus potent AR inhibition improves long term remission rates with salvage RT in high risk men. See our STARTAR trial #ASCO23 abstract 5016 Tian Zhang, MD, MHS The PCCTC DCI Center for Prostate & Urologic Cancers Duke Cancer Dan George

#prostatecancer section of posters seemed like Duke alley. Duke Cancer